Is Nanobac Pharmaceuticals Stock a Good Investment?
Nanobac Pharmaceuticals Investment Advice | NNBP |
- Examine Nanobac Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Nanobac Pharmaceuticals' leadership team and their track record. Good management can help Nanobac Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Nanobac Pharmaceuticals' business and its evolving consumer preferences.
- Compare Nanobac Pharmaceuticals' performance and market position to its competitors. Analyze how Nanobac Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Nanobac Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Nanobac Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Nanobac Pharmaceuticals Incorporated stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Nanobac Pharmaceuticals Incorporated is a good investment.
Not Rated
Examine Nanobac Pharmaceuticals Stock
Researching Nanobac Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years. Nanobac Pharmaceuticals had 1:4 split on the 27th of March 2000.
To determine if Nanobac Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nanobac Pharmaceuticals' research are outlined below:
| Nanobac Pharmaceuticals generated a negative expected return over the last 90 days | |
| Nanobac Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Nanobac Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K. | |
| Nanobac Pharmaceuticals Incorporated currently holds about 3.93 K in cash with (910.89 K) of positive cash flow from operations. | |
| Nanobac Pharmaceuticals has a very weak financial position based on the latest SEC disclosures |
Nanobac Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 124.75 K.Market Cap |
|
Nanobac Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (97.85) | (92.96) | |
| Return On Capital Employed | 9.33 | 9.79 | |
| Return On Assets | (1.05) | (1.10) | |
| Return On Equity | 2.51 | 2.63 |
Determining Nanobac Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Nanobac Pharmaceuticals is a good buy. For example, gross profit margin measures Nanobac Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nanobac Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Nanobac Pharmaceuticals' management efficiency
Nanobac Pharmaceuticals has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nanobac Pharmaceuticals' management efficiency ratios could be used to measure how well Nanobac Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nanobac Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 11/30/2024, Return On Equity is likely to grow to 2.63, though Return On Tangible Assets are likely to grow to (92.96). As of 11/30/2024, Change To Liabilities is likely to grow to about 632.9 K, while Total Current Liabilities is likely to drop slightly above 4.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.01) | (0.01) | |
| Tangible Book Value Per Share | (0.04) | (0.04) | |
| Enterprise Value Over EBITDA | (0.80) | (0.84) | |
| Price Book Value Ratio | (20.98) | (22.03) | |
| Enterprise Value Multiple | (0.80) | (0.84) | |
| Price Fair Value | (20.98) | (22.03) | |
| Enterprise Value | 33.6 M | 29.2 M |
Nanobac Pharmaceuticals' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta (35.70) |
Basic technical analysis of Nanobac Stock
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nanobac Pharmaceuticals, as well as the relationship between them.Nanobac Stock media impact
Far too much social signal, news, headlines, and media speculation about Nanobac Pharmaceuticals that are available to investors today. That information is available publicly through Nanobac media outlets and privately through word of mouth or via Nanobac internal channels. However, regardless of the origin, that massive amount of Nanobac data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nanobac Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nanobac Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nanobac Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nanobac Pharmaceuticals alpha.
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.